-
-
-
-
-
-
-
Amneal reports positive interim results for CREXONT in Parkinson's study
-
-
-
-
-
-
-
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
-
-
-
-
-
-
-
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
-
-
-
-
-
-
-
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
-
-
-
-
-
-
-
Amneal gets FDA approval for first generic iohexol injection
-
-
-
-
-
-
-
Amneal to Report Third Quarter 2025 Results on October 30, 2025
-
-
-
-
-
-
-
Amneal receives FDA approval for generic risperidone injection
-
1,205,328 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

